Track Brooks Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 4.22 %
Low
59.0
High
63.0
1 Month returns: -9.87 %
Low
57.5
High
73.0
1 Year returns: -57.43 %
Low
36.3
High
165.9
3 Year CAGR: -15.64 %
Low
36.3
High
198.9
5 Year CAGR: -12.60 %
Low
36.3
High
198.9
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Brooks Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Brooks Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Brooks Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Brooks Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Brooks Laboratories Ltd.?
The current share price of Brooks Laboratories Ltd. is ₹ 63.00 as of 12 Aug 2026.
What is the market capitalisation of Brooks Laboratories Ltd.?
The market capitalisation of Brooks Laboratories Ltd. stands at ₹ 185.58 Cr.
What is the PE ratio of Brooks Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Brooks Laboratories Ltd. is 7.55 as of the latest trailing twelve months data.
What is the ROE and ROCE of Brooks Laboratories Ltd.?
Brooks Laboratories Ltd. has a Return on Equity (ROE) of 22.27% and a Return on Capital Employed (ROCE) of 4.62% as per the latest financial reports.
What is the 52-week high and low of Brooks Laboratories Ltd.?
The 52-week high of Brooks Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Brooks Laboratories Ltd.?
The dividend yield of Brooks Laboratories Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Brooks Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 9.90% and retail/public investors hold 34.19% of Brooks Laboratories Ltd. shares.
What sector does Brooks Laboratories Ltd. belong to?
Brooks Laboratories Ltd. operates in the Healthcare sector.
What is the beta of Brooks Laboratories Ltd.?
The beta of Brooks Laboratories Ltd. is 1.37, indicating its price volatility relative to the broader market. Over the past 1 year, Brooks Laboratories Ltd. has delivered an absolute return of -60.13%.
What is the RSI of Brooks Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Brooks Laboratories Ltd. is 47.14, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Brooks Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Stock is cheap and PE TTM is at a discount to industry median
PE TTM of 7.55 indicates that the stock is cheap on a standalone basis. Discount to industry median P/E is decent at -74.49%
What is P/E Ratio?
Median: 29.6
Value 7.55
0.33286.35
Negative
Weak price momentum
Price Momentum score of 15.7 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term
What is Price Momentum score?
15.7 / 100
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 45.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
45.9 / 100
Stock in ESM list
The stock has been places in Enhanced Surveillance Measure (ESM) list (ESM - I (34)).
Thinly traded (low daily turnover)
The stock is thinly traded with combined (NSE & BSE) daily turnover (21-day average) of 0.139102.
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
Aryan Mahajan
Promoter Group
November-2024
Market Sale (Disposal)
17th Nov 2024
4.60 %
₹ 137.40
4.80 lac
₹ 6.60 cr
Atul Ranchal
Promoter
November-2024
Market Sale (Disposal)
17th Nov 2024
22.36 %
₹ 137.40
2.00 lac
₹ 2.75 cr
Atul Ranchal
Promoter
November-2024
Market Sale (Disposal)
17th Nov 2024
23.86 %
₹ 136.40
3.95 lac
₹ 5.39 cr
Atul Ranchal
Promoter
November-2024
Market Sale (Disposal)
17th Nov 2024
23.86 %
₹ 136.40
3.95 lac
₹ 5.39 cr
Saras Gupta
Promoter Group
November-2024
Market Sale (Disposal)
17th Nov 2024
3.07 %
₹ 137.40
1.15 lac
₹ 1.59 cr
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Company Profile
Overview of Brooks Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, a...